JCR Pharmaceuticals Co., Ltd. announced appointment of Pascal Yoshida, M.D. as Senior Director, Head of Medical Affairs Unit, effective from July 1, 2022.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
586 JPY | +1.56% | +6.92% | -49.91% |
May. 31 | JCR Pharmaceuticals' Full-Year Profit Up 46% | MT |
May. 27 | Jefferies Adjusts JCR Pharmaceuticals’ Price Target to 560 Yen From 1,200 Yen, Keeps at Hold | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-49.91% | 461M | |
+42.60% | 748B | |
+32.34% | 598B | |
-5.74% | 356B | |
+17.79% | 325B | |
+3.37% | 283B | |
+16.47% | 245B | |
+9.26% | 211B | |
-5.07% | 209B | |
+6.74% | 165B |
- Stock Market
- Equities
- 4552 Stock
- News JCR Pharmaceuticals Co., Ltd.
- JCR Pharmaceuticals Co., Ltd. Appoints Pascal Yoshida as Senior Director, Head of Medical Affairs Unit